| Name | Title | Contact Details |
|---|
Contessa operates a risk based model, Home Recovery Care, that combines all the essential elements of inpatient hospital care in the comfort of patients` homes. We bring together our evidenced-based home recovery care models for acute care, post-acute care and surgical procedures with administrative support services and a proprietary health informatics platform.
Barnabas Health provides treatment and services for more than two million patients each year: 198,000 inpatients and Same Day Surgery patients; 452,000 Emergency Department patients; and 1.5 million outpatients; and delivers more than 18,300 babies annually. Our 18,200 employees, 4,600 physicians and 445 residents and interns are united in our mission to deliver the highest quality of care in the best possible environment. Among our nationally renowned services are: New Jersey’s only certified burn treatment facility, world-class cardiac surgery services for adults; the oldest, most experienced heart transplant program in New Jersey ranked by volume in the top 10 in the nation; the only lung transplant program in New Jersey; one of the country’s most comprehensive robotic surgery services, six nationally certified chest pain centers; accredited certified comprehensive and primary stroke centers, two kidney transplant centers which are in the top 10 of 240 programs in the country; a renowned neurology and neurosurgery program; highly respected assistive reproductive technology program; comprehensive cancer services for adults and children; nationally recognized geriatric services and renowned women’s and children’s services. Throughout Barnabas Health, our dedicated physicians, nurses and health professionals are committed to providing the highest quality of patient care and health education to the community and the region.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Hamilton General Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Hamilton, TX. To find more information about Hamilton General Hospital, please visit www.hamiltonhospital.org